Post-operative Carcinoembryonic Antigen (CEA) Increase as an Indicator of Recurrence After Resection in Colorectal Cancer Patients at Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar
DOI:
https://doi.org/10.26555/eshr.v8i2.16453Keywords:
Carcinoembryonic antigen, Colorectal cancer, Post-operative CEA, Recurrence, Disease-free survivalAbstract
Background: Carcinoembryonic Antigen (CEA) is a glycoprotein utilised as a serological marker for postoperative surveillance of colorectal cancer. Its role in predicting recurrence after curative resection remains a subject of debate.This study aimed to evaluate post-operative CEA as an indicator and predictor of recurrence after resection in colorectal cancer patients, and to determine the disease-free survival (DFS) over 24 months.
Methods: A retrospective cohort study was conducted at the Digestive Surgery Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Bali, from December 2024 to February 2025. A total of 66 patients with stage II–III colorectal cancer who had undergone curative resection (R0) between 2018 and 2022 were enrolled. Post-operative CEA was measured at a minimum of four months after resection. Patients were followed for recurrence and disease-free survival over a 2-year period.
Results: Of 66 patients, 43 (65.2%) experienced recurrence. Post-operative CEA >5 ng/mL was significantly associated with recurrence (RR = 1.82; 95% CI: 1.357–2.444; p = 0.001). ROC curve analysis identified an optimal CEA fluctuation cut-off of 1.01 ng/mL as a “surveillance threshold” for predicting recurrence (AUC = 0.821; sensitivity 72.1%; specificity 95.7%). The optimal post-operative CEA cut-off was 4.11 ng/mL (AUC = 0.696; p = 0.009). Two-year DFS was significantly lower in patients with post-operative CEA >4.11 ng/mL versus those with CEA ≤4.11 ng/mL (40% vs. 63%; p = 0.001).
Conclusion: Elevated post-operative CEA was significantly associated with recurrence after resection in colorectal cancer patients. A CEA increase of 1.01 ng/mL can serve as a “surveillance threshold” to indicate possible recurrence. CEA should be combined with radiological imaging for optimal surveillance.
References
Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Kanker Kolorektal. Kementerian Kesehatan Republik Indonesia; 2018.
Rudiman R. Kanker kolorektal di Indonesia: Epidemiologi dan tantangan klinis. J Bedah Indones. 2023;11(2):45-55.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
Sayuti M. Kanker kolorektal di Indonesia: Perspektif epidemiologi. J Med Indones. 2019;7(1):10-18.
Barata IGN, Sueta MA, Adnyana MS. Hubungan antara kadar carcinoembryonic antigen (CEA) dan stadium kanker kolorektal di RSUP Sanglah tahun 2016-2017. E-J Med Udayana. 2018;7(12):1-5.
Widhyasih RM, Sujatno IGM, Dewi PAAK. CEA dan kanker kolorektal: Tinjauan klinis. J Biomedis Klin Indones. 2019;5(2):72-78.
Beck DE. Colon carcinoma: Epidemiology, etiology, pathology, and diagnosis. In: Beck DE, Wexner SD, Hull T, Longo WE, eds. Gordon and Nivatvongs’ Principles and Practice of Surgery for the Colon, Rectum, and Anus. Vol 4. Thieme Publishers; 2019:400-457.
Lee TH, Park IJ, Kim JH. Serial CEA monitoring after curative resection of colorectal cancer. Colorectal Dis. 2023;25(5):921-930.
Zhang C, Gu L, Cai Z. Prognostic value of postoperative CEA in detecting recurrence and metastasis of colorectal cancer. Oncol Lett. 2020;19(3):2411-2418.
Wang R, Liu Y, Chen X. Accuracy of CEA in detecting early recurrence of colorectal cancer: A meta-analysis. Front Surg. 2023;10:1145823. doi:10.3389/fsurg.2023.1145823
Noh GT, Ann YS, Cheong C, Han J. Validation of CEA as a surveillance marker for the detection of colorectal cancer recurrence. Medicine (Baltimore). 2020;99(33):e21758. doi:10.1097/MD.0000000000021758
Morimoto Y, Maeda K, Nagahara H. High postoperative CEA predicts poor prognosis in stage II colon cancer. Oncol Lett. 2022;23(4):1-8.
Pu H, Huang W, Yang L. Postoperative CEA and recurrence-free survival in colon cancer. Front Oncol. 2022;12:881748. doi:10.3389/fonc.2022.881748
Fekete Z, Ignat P, Gligor L, Todor N, Muntean AS, Gherman A, Eniu D. Diagnosis of relapse of colorectal adenocarcinoma through CEA fluctuation. Y Rep. 2024;7(3):60. doi:10.3390/reports7030060
Alzahrani SM, Al Doghaither HA, Al-Ghafari AB. General insight into cancer: An overview of colorectal cancer (Review). Mol Clin Oncol. 2021;15(6):271-271. doi:10.3892/mco.2021.2433
Kankanala VL, Mukkamalla SKR. Carcinoembryonic antigen. StatPearls. 2023. https://www.ncbi.nlm.nih.gov/books/NBK531430/
Amin MB, Edge SB, Greene FL. Colon and Rectum. In: Amin MB, Edge SB, Greene FL, eds. AJCC Cancer Staging Manual. Vol 8. Springer; 2017:251-274.
Filiz AI, Sucullu I, Kurt Y, Karakas DO, Gulec B, Akin ML. Persistent high postoperative carcinoembryonic antigen in colorectal cancer patients - Is it important? Clin Sao Paulo. 2009;64(4):287-294. doi:10.1590/S1807-59322009000400004
Yang KM, Park IJ, Lee JL, Lim SB, Yu CS, Kim JC. Abnormal postoperative CEA kinetics as an independent prognostic factor for colorectal cancer recurrence. Medicine (Baltimore). 2016;95(11):e2958. doi:10.1097/MD.0000000000002958
Kim HS, Lee MR. Postoperative serum carcinoembryonic antigen level as a predictor of recurrent disease after curative resection of colorectal cancer. Ann Coloproctology. 2013;29(4):139-143. doi:10.3393/ac.2013.29.4.139
Lee JH, Lee SW. The roles of carcinoembryonic antigen in liver metastasis and therapeutic approaches. Gastroenterol Res Pract. 2017;2017(PMID:28588612):1-7. doi:10.1155/2017/7521987
Wang R, Liu Y, Chen X. Accuracy of CEA in detecting early recurrence of colorectal cancer: A meta-analysis. Front Surg. 2023;10:1145823. doi:10.3389/fsurg.2023.1145823
Pu H, Huang W, Yang L. Postoperative CEA and recurrence-free survival in colon cancer. Front Oncol. 2022;12:881748. doi:10.3389/fonc.2022.881748
Morimoto Y, Maeda K, Nagahara H. High postoperative CEA predicts poor prognosis in stage II colon cancer. Oncol Lett. 2022;23(4):1-8.
Noh GT, Ann YS, Cheong C, Han J. Validation of CEA as a surveillance marker for the detection of colorectal cancer recurrence. Medicine (Baltimore). 2020;99(33):e21758. doi:10.1097/MD.0000000000021758
Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol. 2009;18(1):15-24. doi:10.1016/j.suronc.2008.05.008
Barata IGN, Sueta MA, Adnyana MS. Hubungan antara kadar carcinoembryonic antigen (CEA) dan stadium kanker kolorektal di RSUP Sanglah tahun 2016-2017. E-J Med Udayana. 2018;7(12):1-5.
Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol. 2009;18(1):15-24. doi:10.1016/j.suronc.2008.05.008
Widhyasih RM, Sujatno IGM, Dewi PAAK. CEA dan kanker kolorektal: Tinjauan klinis. J Biomedis Klin Indones. 2019;5(2):72-78.
Zhang C, Gu L, Cai Z. Prognostic value of postoperative CEA in detecting recurrence and metastasis of colorectal cancer. Oncol Lett. 2020;19(3):2411-2418.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Cokorda Bagus Nurparma Putra, Made Agus Dwianthara Sueta, Ketut Sudartana
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with ESHR agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
